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Evidence-based guidelines for managing patients with primary
ER+ HER2− breast cancer deferred from surgery due to
the COVID-19 pandemic
Mitch Dowsett1,2✉, Matthew J. Ellis 3,4,5, J. Michael Dixon6, Oleg Gluz7,8,9, John Robertson10, Ronald Kates11, Vera J. Suman12,
Arran K. Turnbull13, Ulrike Nitz7, Matthias Christgen14, Hans Kreipe14, Sherko Kuemmel15, Judith M. Bliss16, Peter Barry17,
Stephen R. Johnston17, Samuel A. Jacobs18, Cynthia X. Ma19, Ian E. Smith17 and Nadia Harbeck 11,20
Many patients with ER+ HER2− primary breast cancer are being deferred from surgery to neoadjuvant endocrine therapy (NeoET)
during the COVID-19 pandemic. We have collated data from multiple international trials of presurgical endocrine therapy in order
to provide guidance on the identification of patients who may have insufficiently endocrine-sensitive tumors and should be
prioritised for early surgery or neoadjuvant chemotherapy rather than NeoET during or in the aftermath of the COVID-19 pandemic
for safety or when surgical activity needs to be prioritized. For postmenopausal patients, our data provide strong support for the
use of ER and PgR status at diagnosis for triaging of patients into three groups in which (taking into account clinical factors): (i)
NeoET is likely to be inappropriate (Allred ER <6 or ER 6 and PgR <6) (ii) a biopsy for Ki67 analysis (on-treatment Ki67) could be
considered after 2–4 weeks of NeoET (a: ER 7 or 8 and PgR <6 or b: ER 6 or 7 and PgR ≥6) or (iii) NeoET is an acceptable course of
action (ER 8 and PgR ≥6). Cut-offs for percentage of cells positive are also given. For group (ii), a high early on-treatment level of
Ki67 (>10%) indicates a higher priority for early surgery. Too few data were available for premenopausal patients to provide a
similar treatment algorithm. These guidelines should be helpful for managing patients with early ER+ HER2− breast cancer during
and in the aftermath of the COVID-19 crisis.
npj Breast Cancer            (2020) 6:21 ; https://doi.org/10.1038/s41523-020-0168-9
INTRODUCTION
In many countries severely affected by the COVID-19 pandemic
the surgical management of primary breast cancer is being
confined to patients at highest risk for early disease progression.
Thus, surgery for ER+ HER2− tumors (>70% of the overall breast
cancer population) is being frequently deferred in favour of
neoadjuvant endocrine therapy (NeoET) because of patient safety
concerns and resource availability. In severely affected areas, it
may be many months before surgery for patients on NeoET
becomes available, raising concerns that this approach maybe
suboptimal. A recent publication recommended approaches for
the general management of breast cancer during the COVID-19
crisis and proposed the use of endocrine treatment and delay of
surgery until after COVID-19 for T1N0ER+ HER2− breast cancer
and considering this for T2 or N1 ER+ HER2− disease1.
NeoET has been used for many years to down-stage tumors for
improved surgical outcome. Generally, NeoET provides good initial
control of primary breast cancer for several months or even years,
but local progression can occur, particularly with prolonged
treatment and these events are associated with worse outcomes.
Data from a meta-analysis of randomised clinical trials of
immediate surgery with tamoxifen compared to tamoxifen alone
(with surgery only in the event of local progression) for primary
breast cancer in women aged 70 years or older alone shows a 29%
(proportional) reduction in distant recurrence rates and a 27%
(proportional) reduction in breast cancer mortality rates in those
allocated surgery, without any increase in non-breast cancer
deaths (EBCTCG personal communication). Thus, the accurate
identification of patients most likely to be poorly controlled by
NeoET would allow their surgery or systemic treatment to be
prioritised during or in the aftermath of COVID19 according to
local circumstances. Conversely, identification of those likely to
experience adequate tumor control by NeoET over a period of
surgical deferment would be reassuring.
In order to address these issues, we have formed a consortium
of international study groups comprising some of the widest
experience of NeoET globally. The immediate objective was to
review the published data that underpins the application of NeoET
in more normal circumstances and to collate this information with
previously unpublished data from many thousands of patients in
ongoing studies to produce a simple algorithm for patient
management. Given the time sensitivity of this matter, the details
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of the populations and methods provided in this paper have been
reduced compared with that we would normally provide. In due
course, detailed data will be provided. Relevant details of the trials
involved in one or more of our analyses, including the IRB
approvals are given in Table 1.
We emphasise that the approach we propose is currently a
temporary measure where clinical safety or resource issues related
to the COVID19 pandemic impact the availability of surgery; it is
not a substitute for standard surgical care once circumstances
permit.
In creating these guidelines, we have been mindful of the
following:
1. Interventions should fall within current clinical pathways, in
terms of laboratory tests performed and patient care
procedures as much as possible.
2. The patient selection process should be as straightforward
for clinical staff to implement and relevant to as many
patients as possible.
3. We should provide biomarker cut-off values for different
scoring systems (eg Allred score, percentage cells positive)
to make them internationally useable/applicable.
4. The guidance must be considered in conjunction with
clinical factors (eg tumor burden, patient age and co-
morbidities).
RESULTS AND DISCUSSION
Proposed triaging approach for remaining on NeoET, considering
alternative treatments or additional diagnostic procedures
The data presented in the sections below support the approach of
identification of three groups of naturally postmenopausal
patients that depends on the baseline expression of estrogen
receptor (ER) and progesterone receptor (PgR) and an early on-
treatment biopsy for Ki67 where indicated. Figure 1 summarises
the approach separately for ER/PgR Allred scores (a) and
percentage of cells positive (b). In some centres where Ki67 is
routinely measured at diagnosis, baseline Ki67 can provide an
additional means of identifying those patients who may be
excluded from on-treatment biopsy.
Group 1: (~5%) should NOT be considered for NeoET. This is the
group most likely to show no response and possible progression
during protracted NeoET. Their endocrine responsiveness is poor
overall, and they have a high incidence of on-treatment Ki67 >
10% which portends a poor prognosis.
Group 2: (~35%) may be considered for NeoET, provided that
endocrine responsiveness is demonstrated as follows. In patients
with Ki67 ≥ 15% at diagnosis, a core-biopsy should be taken after
2–4 weeks or later if more convenient. If on-treatment Ki67 > 10%,
patients should be considered for other options such as surgery or
neoadjuvant chemotherapy rather than continuing on NeoET; if
on-treatment core biopsy and/or Ki67 analysis are unavailable,
enhanced monitoring should be performed. Regarding the
feasibility of on-treatment biopsies, if a surgical marker has not
been placed, a patient can be started on NeoET and the surgical
marker placed at the time of the on-treatment biopsy.
Group 3: (~60%) may remain on NeoET for at least 6 months. This
group have very good endocrine responsiveness and a low
incidence of on-treatment Ki67 > 10% overall. However, if baseline
Ki67 is known to be >30%, an on-treatment biopsy should be
considered as in Group 2.
Marti and Sanchez-Mendez2 have recently advocated the use of
NeoET with biopsy for Ki67 and dichotomisation at 10% but provided
no strategy for minimizing the numbers requiring on-treatment biopsy.Ta
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ER, PgR at diagnosis and clinical response
Studies in which ER+ PgR+ or simply high-ER score tumors (eg.,
H-score > 100) were selected for NeoET reported <5% of tumors
progressing de novo on ET3,4. In the first, a phase 2 study
conducted in Edinburgh, all tumors were ER+ and 92% were also
PgR+. Patients were treated with neoadjuvant letrozole and 23/24
(96%) had a >25% reduction in tumor volume over the 3-month
study period. In a second study, only 1/47 (~2%) of tumors with an
H-score of >100 had de novo progression during the preoperative
phase of ET treatment. The Edinburgh group recently audited their
data on 456 postmenopausal patients treated with letrozole for a
mean of 206 days between 2001 and 2016. The 4% of cases with
Allred ER scores of 5 or 6 showed substantially poorer regression
than those with Allred scores >6 (mean absolute reduction in
largest volume= 7.2% and 34.4%, respectively).
These data suggest that high initial ER levels or a combination
of both ER+ and PgR+ could be used to select a group of tumors
highly likely to be controlled on NeoET. This approach alone still
leaves a significant proportion of ER+ tumors that may progress
during NeoET, particularly if NeoET must be prolonged, and thus
additional approaches to response assessment are required if
Fig. 1 Flowcharts to show use of ER and PgR categories and on-NeoET Ki67 for directing postmenopausal patients with primary ER+
HER2-breast cancer towards NeoET or surgery/neoadjuvant chemotherapy based on Allred scores or based on % cells positive. Allred
scores are created by summing two separate scores: (the overall intensity of stained cells, none= 0, weak= 1, intermediate= 2, strong= 3)+
(percentage of cells staining positive none= 0, <1%= 1, 1–10%= 2, 11–33%= 3, 34–66%= 4, ≥67%= 5).
M. Dowsett et al.
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NeoET is to be used optimally and without adversely affecting
long-term outcomes.
Early on-treatment Ki67 and clinical response
Presurgical use of ET can be either short-term, generally for about
2–4 weeks during the “window-of-opportunity” prior to scheduled
surgery, or longer-term, usually for at least 3 months and in many
cases up to 6 months and sometimes beyond5. The focus in the
former, so-called window trials, is on obtaining biological response
data including the proliferation marker Ki67. In the longer term,
the primary goal of NeoET is downstaging of the disease and
sometimes deriving biological response data for adjuvant treat-
ment planning.
In several clinical trials of therapeutic NeoET, a biopsy at
2–4 weeks after starting NeoET has been taken for Ki67
measurement. There is substantial evidence for the on-treatment
values providing strong prognostic information6,7,8. There are,
however, few published data where the Ki67 data are considered
in relation to clinical response or local tumor control.
We have now examined the data from two previously published
NeoET clinical trials in postmenopausal patients to examine this
relationship: anastrozole±gefitinib (IL1839/223)9 and letrozole
±palbociclib (PALLET)10. Recent studies have consistently assessed
a Ki67 cut-off at 10% as either a primary end-point or key factor in
treatment allocation (POETIC5, WSG-ADAPT11, Z10317, ALTER-
NATE12), and this pre-specified cut-off has been employed in all
of the data analyses performed below.
Patients with HER2+ disease were excluded at recruitment from
PALLET, and those entered into IL1839/223 were excluded from
the current analysis. Gefitinib has no significant impact on either
Ki67 or clinical response9, so all patients in IL1839/223 starting on
anastrozole for 2 weeks were included in this analysis; for PALLET
only those patients in the letrozole alone arm were included,
because palbociclib has profound antiproliferative effects in
addition to those seen with letrozole10. For each study, 4
categories of residual, tumor size at the end of NeoET were
prospectively developed based on 1-dimensional ultrasound
measurements: >90%; <90%, ≥70%; <70%, ≥50%; <50% of
baseline. The proportion of cases with 2-week Ki67 values
dichotomized at 10% in each of these categories is are shown in
Table 2. It is clear that the better the Ki67 suppression at 2 weeks
the greater the tumor size reduction from baseline, with the two
sets of data producing similar results: in both trials, about 5 times
as many patients had 2-week Ki67 > 10% among those whose
tumors regressed poorly (<10% decrease), compared with those
whose tumors regressed by >50%. For IL1839/223, p-for trend=
0.0504, and for the letrozole arm of PALLET, p= 0.02; summating
the two sets of data, p= 0.002.
In the Z1031B study of neoadjuvant aromatase inhibitors13, of
the 214 patients with Ki67 measured after 2–4 weeks, 165 (77%)
patients had values ≤ 10% and of this group three patients
showed progressive disease at 16 weeks. Building on these data,
the ALTERNATE trial triaged postmenopausal patients with Ki67 >
10% after 4 weeks’ NeoET (anastrozole alone, fulvestrant alone, or
the combination) to chemotherapy, whereas those with Ki67 ≤
10% are maintained on anastrozole ± fulvestrant for 24 weeks
before surgery. Reassuringly, only about 2% of patients main-
tained on NeoET experienced progression over that time, of whom
half were confirmed radiologically.
Overall, these combined data provide a strong rationale for
assessment of Ki67 after 2–4 weeks as a criterion for selecting
patients who can safely be maintained on NeoET. However, during
the COVID-19 pandemic, imaging-guided biopsies are not always
readily available. In view of the direct relationship with clinical
response as described above, we have evaluated whether ER and
PgR expression at diagnosis can be used to reduce the number of
patients for whom on-treatment biopsy is needed, and whether
baseline Ki67 (if available) can further inform the decision.
Hormone receptor status and early on-treatment Ki67: a means of
triaging patients
Higher levels of ER expression are known to relate to greater
proportional benefit from adjuvant endocrine therapy14 and to
relate to greater Ki67 suppression between baseline and 2 weeks,
with aromatase inhibitors or tamoxifen15. Although PgR+ and PgR
− cases show similar proportional benefit from adjuvant
tamoxifen, PgR+ tumors have better prognosis, demonstrate
greater clinical response to endocrine therapy and show greater
Ki67 suppression with aromatase inhibitors or tamoxifen. We have
therefore examined the degree to which ER and PgR status are
associated with 2-week Ki67 in POETIC, ADAPT, PALLET and
IL1839/223.
Our training analysis was conducted on data from a case-
control (relapses vs non-relapses) study underway in POETIC.
Receptor expression categories were derived from this exercise,
then subsequently tested in the other trials to examine their
validity. In each case, the data were categorised according to the
Allred scores and subsequently according to percent ER+ cells to
provide wide applicability. For POETIC, PALLET, and IL1839/223,
the Allred scores were derived as close approximations from the
ER and PgR H-scores.
Table 3 shows the number and proportion of Ki67 values ≤ 10%
and >10% in POETIC, according to Allred scores for ER levels and
PgR, with the latter dichotomised at ≤5 vs ≥6. This dichotomy
equates closely to 10% of cells PgR positive. Below, the PgR
groups are termed PgR− and PgR+, according to this cut-off.
Cases with ER scores of ≤5 had a 65% incidence of Ki67 > 10%
at 2 weeks. Tumors with an ER approximating to an Allred score of
6 but that were additionally PgR−, also had a high (47%)
incidence of 2-week Ki67 > 10%. In contrast, tumors with an ER H-
score of >175, approximating to an Allred score of 8, and that
were also PgR+ had only a 15% incidence of 2-week Ki67 > 10%.
In between these two extremes, the groups that formed Allred ER
7 or 8 but PgR− showed a 32% incidence of 2-week Ki67 > 10%,
similar to the 27% incidence in those with Allred ER 6 or 7 and PgR
+.
From POETIC, we have therefore defined three groups with
Allred scores as shown in Table 4. Data that emerge from POETIC
using these categories are shown in Table 5. Given that many
centres use percentage (%age) ER/PgR scoring, we also developed
groupings based on %ages based on data from POETIC shown in
Table 6. These groupings are also shown in Table 4 and data that
emerge from POETIC using these categories are shown in Table 5.
Table 2. Relationship of 2-week Ki67 and tumor shrinkage (single
dimension RECIST) for IL1839/223 study, anastrozole only to 2 weeks ±
gefitinib to 16 weeks, p for trend= 0.0504 and PALLET study (Letrozole
only—group A), p for trend= 0.02.
Residual tum size % baseline n Ki67 > 10% n Ki67 > 10% (%)
IL1839/223
>90 22 7 32
<90, ≥70 30 7 23
<70, ≥50 37 6 16
<50 14 1 7
PALLET study
≥90 22 8 36
<90 to ≥70 24 7 29
<70 to ≥50 20 3 15
<50 15 1 7
M. Dowsett et al.
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It can be seen in Table 5 that the proportions of patients in the
groupings were very similar. We therefore tested the validity of
the Allred subgroupings in the combined data from PALLET+
IL1839/223 and from the ADAPT trial. For the latter, we treated the
data from postmenopausal AI-treated patients separately from
that of premenopausal patients, who mostly received tamoxifen
(data shown in detail in Table 7 according to Allred scores). Table 8
show the data from PALLET+ IL1839/223 and ADAPT postmeno-
pausal patients, respectively. The proportion of patients with
Ki67 > 10% or ≤10% in groups 1, 2, and 3 are very similar to those
in POETIC. Of particular note, the proportions of patients with
Ki67 > 10% in group 2 were 30% in POETIC, 32% in PALLET+
IL1839/223 and 28% in ADAPT postmenopausal. In addition to
percentages, the ADAPT trial also provided centrally performed
Allred scores; the similarity between the study results supports the
approximations to Allred scores made in POETIC, PALLET and
IL1839/223.
Tables 5 and 8 identify the patients who, on the basis of ER/PgR
baseline status and on-treatment Ki67, should be considered for
longer-term NeoET or conversely should not continue on NeoET.
In PALLET+ IL1839/223 and ADAPT postmenopausal patients, the
proportions of patients who can remain on NeoET are very similar
at 86% and 85%, respectively. From the POETIC data, the
proportion was a little lower, which was expected, as this is a
case-controlled cohort with 50% of the population experiencing a
relapse. For POETIC, the overall proportion of patients recom-
mended for on-treatment biopsy was 33% (110/338) if based on
Allred scores and 42% if based on %age of cells staining; for
PALLET/ IL1839/223 the proportion was 33% (85/257), and for
ADAPT postmenopausal patients it was 41% (793/1925).
Use of baseline Ki67 for decreasing the proportion recommended
for on-treatment biopsy
Baseline (i.e., pre-NeoET) Ki67 values are rarely below values
obtained after short-term NeoET: in POETIC, 743/776 tumors had
Ki67 ≤ 10% after 2 weeks among those that were ≤10% at
diagnosis. To determine whether assessing (or when already
analysed accessing) pre-NeoET Ki67 values could reduce the
proportion of patients recommended for biopsy, we examined the
relationship of pre-NeoET Ki67 values with on-treatment
Ki67 specifically in Group 2. We applied cut-off values of 10%,
15%, and 20% to the pre-NeoET Ki67 values for three trial
populations (Table 9).
In POETIC, 43 (39%) of the Group 2 population had on-
treatment Ki67 values ≤ 10% if they had values ≤ 15% at diagnosis.
Four (9%) of the 43 had values above 10% at 2 weeks. In contrast,
in the 27/67 (40%) patients with pre-NeoET Ki67 values >15% had
on-NeoET Ki67 values of ≤10%.
In ADAPT post-menopausal patients, only 44/566 (7.8%) with
baseline Ki67 ≤ 10% had an on-treatment Ki67 > 10%. Patients in
Group 2 with baseline Ki67 ≤ 15% had a > 85% likelihood of
obtaining on-treatment Ki67 ≤ 10%. This represent 44% of Group 2
patients (of note, the cutoff of 15% also applies if ER and PgR
measurements were expressed according to Allred score).
Similar proportions of patients can be seen in each of the
subdivisions of the Z1031B population with ER Allred scores of
6–8.
With regard to Group 3, post-menopausal ADAPT patients with
baseline Ki67 measurements ≤ 30% had a > 85% likelihood of
obtaining on-treatment Ki67 ≤ 10%. However, among patients
with baseline Ki67 > 30% (who comprise only ~20% of Group 3),
only about 57% obtained on-treatment Ki67 ≤ 10%. Thus, for this
subset of Group 3, the authors recommend obtaining an on-
treatment Ki67 measurement (if available) to ensure endocrine
sensitivity before continuing NeoET.
Premenopausal patients
The safety concerns from COVID-19 infection are less in younger
women and there are far fewer data on the long-term clinical
efficacy of NeoET in premenopausal women. There are also fewer
data on the short-term effects on Ki67 than in postmenopausal
women. Consistent suppression of Ki67 was seen with both
tamoxifen and a single 750 mg dose of fulvestrant in an Edinburgh
study with tamoxifen showing a trend for greater suppression16.
DeCensi reported that Ki67 was suppressed by tamoxifen after
4 weeks in premenopausal women, but the values were higher
Table 4. Patient groups based on Allred scores and %age cells
positive for ER and PgR.
Allred score %age cells positive
Group 1 ER < 6 ER ≤ 40%
ER 6 and PgR <6 ER > 40%, ≤65% and PgR ≤ 10%
Group 2 (a) ER7 or 8 and PgR <6 ER > 65% and PgR ≤ 10%
Group 2 (b) ER 6 or 7 and PgR ≥ 6 ER > 40%, ≤90% and PgR > 10%
Group 3 ER 8 and PgR ≥ 6 ER > 90% and PgR > 10%
Table 3. Numbers (percentage) of POETIC patients with on-treatment Ki67 values >10% or ≤10%, according to ER and PgR H-scores and
approximate Allred scores.
PgR Allred < 6 PgR Allred ≥ 6 Total
ER H-scores Ki67 > 10% Ki67 ≤ 10% Total
numbers
Ki67 > 10% Ki67 ≤ 10% Total
numbers
Ki67 > 10% Ki67 ≤ 10% Total
numbers
ER > 1 and ≤75 (Allred equiv 2–5) 15 (83%) 3 (17%) 18 1 (20%) 4 (80%) 5 16 (70%) 7 (30%) 23
ER > 75 and ≤150 (Allred equiv. 6) 7 (47%) 8 (53%) 15 5 (26%) 14 (74%) 19 12 (35%) 22 (65%) 34
ER > 150 and ≤175 (Allred equiv. 7,8) 3 (30%) 7 (70%) 10 7 (28%) 18 (72%) 25 10 (29%) 25 (71%) 35
ER > 175 and ≤200 6 (30%) 14 (70%) 20 11 (17%) 53 (83%) 64 17 (20%) 67 (80%) 84
ER > 200 and ≤225 5 (29%) 12 (71%) 17 9 (16%) 48 (84%) 57 14 (19%) 60 (81%) 74
ER > 225 and ≤250 4 (44%) 5 (56%) 9 4 (15%) 23 (85%) 27 8 (22%) 28 (78%) 36
ER > 250 and ≤275 0 (0%) 4 (100%) 4 2 (12%) 15 (88%) 17 2 (10%) 19 (90%) 21
ER > 275 and ≤300 1 (17%) 5 (83%) 6 2 (8%) 23 (92%) 25 3 (10%) 28 (90%) 31
Total ER > 175 and ≤300 (Allred equiv 8) 16 (29%) 40 (71%) 56 28 (15%) 162 (85%) 190 44 (18%) 202 (82%) 246
M. Dowsett et al.
5
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2020)    21 
than those in postmenopausal women both before and at the end
of treatment8. These findings are consistent with the higher
proportion (60.5% vs. 24.4%) of pre- (88.6% treated with
tamoxifen) vs. postmenopausal patients (91.9% treated with AI)
in ADAPT having on-treatment Ki67 > 10%. The difference may
result from Ki67 not being fully suppressed by tamoxifen within
3 weeks, due to the much higher competing estrogen levels in
premenopausal women.
In Table 8, it can be seen that there were no strong relationships
between on-treatment Ki67 and ER or PgR levels in premenopau-
sal patients in ADAPT, so these levels therefore cannot be
recommended to reduce the number of patients who could be
spared an on-treatment biopsy, even considering baseline Ki67.
Overall, it seems reasonable to use on-treatment Ki67 if there is
a clinical need to prioritise NeoET for premenopausal patients, but
there are few clinical data to directly support this so we are unable
to recommend this. In ADAPT pre-menopausal patients, the
percentages of patients with on-treatment Ki67 ≤ 10% were
25.8%, 37.0%, and 43.6% in Groups 1, 2, and 3, respectively.
Enhanced monitoring when on-treatment biopsy for Ki67 is
unavailable
During the COVID-19 pandemic, resources for imaging-guided
biopsies may be restricted and on-treatment biopsy for Ki67
unavailable for some patients. In the Edinburgh group’s audit of
456 postmenopausal patients treated with letrozole, a reduction
of at least 15% in relative tumor volume early in treatment
(mean= day 47) was significantly associated with continued
neoadjuvant clinical response. Thus, for those patients in whom
an on-treatment biopsy would otherwise be assessed, an interval
assessment of maximum tumor size as measured clinically and by
ultrasound or mammogram could be considered as an alternative.
Failure to reduce maximum volume by ≥15% at 6 weeks and
≥20% at 3 months is associated with a significantly lower chance
of long-term local control and a worse long-term survival. An on-
treatment biopsy is preferred if resources and safety allow this.
Reliability of Ki67 analysis
It has been widely reported that Ki67 results can vary substantially
between centres17. However, in an early study by the International
Ki67 in Breast Cancer Working Group (KiBCWG)18, analysts at
expert labs were found to have excellent within-lab consistency
(ICC 0.94). Although the labs involved in the studies considered in
the current report have not undertaken formal exchange of
materials, there is evidence for their measurements being similar:
the data relationships between steroid receptor subgroups and
on-treatment Ki67 is very similar; and the ADAPT run-in phase
almost exactly reproduced Ki67 assumptions based on the data
from the Ellis and Dowsett labs19. Moreover, the analyses reported
above for the ADAPT trial provided similar results using locally vs.
centrally determined ER, PgR, and baseline Ki67.
Centres wishing to apply on-treatment Ki67 should confirm that
their Ki67 analysis is operating to similar levels and should contact
the authorship to access material if needed to do so. Differences in
Table 6. Numbers (percentage) of POETIC patients with on-treatment Ki67 values >10% or ≤10%, according to ER and PgR percentage scores and
approximate Allred scores.
ER H-scores PgR ≤ 10% PgR >10% Total
Ki67 > 10% Ki67 ≤ 10% Total numbers Ki67 > 10% Ki67 ≤ 10% Total numbers Ki67 > 10% Ki67 ≤ 10% Total numbers
Allred equiv c.2–5
ER ≤ 40% 9 (75%) 3 (25%) 12 1 (25%) 3 (75%) 4 10 (63%) 6 (37%) 16
Allred equiv c.6
ER > 40, ≤65% 7 (70%) 3 (30%) 10 1 (17%) 5 (83%) 6 8 (50%) 8 (50%) 16
Allred equiv c.7
ER > 65, ≤90% 14 (45%) 17 (55%) 31 10 (33%) 33 (77%) 43 24 (32%) 50 (68%) 74
Allred equiv c.8
ER > 90% 16 (26%) 45 (74%) 61 24 (14%) 148 (86%) 172 40 (17%) 193 (83%) 233
Table 5. Summary of groups 1, 2 and 3 for POETIC.
Based on Allred scores Based on % cells positive
ER/PgR group Ki67 > 10% Ki67 ≤ 10% Total Ki67 > 10% Ki67 ≤ 10% Total
n (%) n (%) n n (%) n (%) n
1 23 (61) 15 (39) 38 17 (65) 9 (35) 26
2 (a) 19 (29) 47 (71) 66 30 (33) 62 (67) 92
2 (b) 12 (27) 32 (73) 44 11 (22) 38 (67) 49
2 (a+ b) 31 (28) 79 (72) 110 41 (30) 100 (72) 141
3 28 (15) 162 (85) 190 24 (14) 148 (86) 172
Total 338 339
Remove from NeoET 69 (20%) 67 (20%)
Remain on NeoET 269 (80%) 272 (80%)
ER/PgR groupings based on Allred scores or percentage cells positive.
Values for Ki67 are on treatment.
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scoring of Ki67 were found by the International KiBCWG to be the
most important source of between-laboratory variability. Consis-
tency of scores is markedly enhanced by adherence to the
methodology for “global scoring” which was validated and
endorsed by the KiBCWG20 and is advocated here. Using this
method, the median baseline Ki67 in ER+ HER2- tumors in the
whole POETIC trial (ie., not just the case-control series described
here) was 14.3% (n= 3452). In ADAPT, median baseline Ki67 was
20% for both pre- and postmenopausal patients (n= 1954 and
2730, respectively). The median baseline Ki67 in ADAPT was
expected to be higher than in POETIC since eligibility for ADAPT
was confined to those that were candidates for (neo)adjuvant
chemotherapy by conventional prognostic criteria.
Clinical factors
Clinical factors such as tumor size and nodal status do not impact
on response to NeoET but do relate to the overall prognosis of
patients. Their interaction with competing factors of advanced age/
frailty and co-morbidity is helpful for decision-making in individual
patients, and assists clinicians in prioritising the individual for
surgery within a larger cohort of patients competing for
appropriate care as in the COVID-19 pandemic. Thus, while the
clinician should take these features into account when making
decisions on appropriateness of NeoET the complexity of the
interactive factors precludes our making precise recommendations.
The appropriateness or advantage of continued NeoET should
be individualised and needs to re-appraised with frequent
regularity as the situation changes in times of a pandemic such
as the current one. While we do not recommend fixed durations
for treatment, if the objective is to promote breast conserving
surgery, 4–6 months is typical and longer can be helpful for larger
tumors. In patients with smaller tumors who are already
candidates for breast conservation, surgery could be as soon as
the availability of resources returns.
The preoperative endocrine prognostic index (PEPI) was derived
from patients in clinical trials where the length of NeoET varied
between 12 and 18 weeks (12 weeks IMPACT/P024 and
16–18 weeks for Z10317). If a longer or shorter period of NeoET
is used, the PEPI approach could still be applied on an individual
basis, since the Ki67 is prognostic after very short periods of time
(2 to 4 weeks). Thus, if a patient’s surgical sample was assigned
PEPI-0 (Pathological stage T1 or T2, N0, Ki67 < 2.7%) and surgery
was conducted when the patients was still on NeoET, post-surgical
management without chemotherapy could be considered.
Genomic assays and use of NeoET
Genomic assays are in widespread use for the selection of those
patients with ER+ HER2− node-negative breast cancer who
should receive adjuvant chemotherapy as well as endocrine
therapy. They estimate risk of distant recurrence on endocrine
therapy alone largely by integrating information on baseline
proliferation and features relating to the likelihood of endocrine
responsiveness. Their main objective is to aid in counselling
patients regarding their individual risk/benefit ratio for the use of
chemotherapy. In contrast to the data presented here, there are
no data on the relationship of genomic assays and local control
with NeoET. Our proposal also has the advantage of undertaking
an on-treatment measurement of the response to endocrine
therapy (2–4 week Ki67). If a genomic assay is undertaken it must
be conducted on a biopsy before starting NeoET since this has a
profound but so far ill-described effect on the expression of many
genes in the tests.
CONCLUSIONS
In summary, based on tumor ER and/or PgR expression at
diagnosis and (if available) baseline Ki67, postmenopausal patients
with hormone receptor positive HER2-negative early breast cancer
can be stratified for immediate surgery or neoadjuvant che-
motherapy (Group 1) and others selected for NeoET (Group 3).
Management of the remaining patients (Group2) is dependent on
Ki67 assessment. Group 2 patients with baseline Ki67 ≤ 15% may
continue on NeoET, while the remainder should be considered for
a biopsy for Ki67 at 2–4 weeks to see if Ki67 ≤ 10%, so they can
continue on NeoET. Group 2 patients whose on-treatment Ki67 is
>10% should not continue on NeoET.
NeoET may also be an option for premenopausal patients and
on-treatment Ki67 may be a helpful guide.
We propose the flow diagrams based on these groupings
(Fig. 1a, b) to assist clinicians in the selection of postmenopausal
patients likely to have acceptable outcomes on NeoET and at the
same time prioritise a smaller group for surgery if operating room
capacity allows, or for neoadjuvant chemotherapy as an
alternative.
The data underpinning these recommendations are strong for
postmenopausal but more limited for premenopausal patients.
This guidance needs to be interpreted in the light of other clinical
features. We have already emphasised that at present these
recommendations are designed to help manage breast cancer
only during the current COVID-19 crisis or during further waves. It
might of course in time prove to have a role in the standard
management of some patients with early breast cancer; this will
require validation by clinical trials.
Table 7. Numbers (percentage) of ADAPT patients with on-treatment Ki67 values >10% or ≤10%, according to ER and PgR Allred scores.
PgR < 6 PgR ≥ 6 Total
ER Ki67 > 10% Ki67 ≤ 10% Total numbers Ki67 > 10% Ki67 ≤ 10% Total numbers Ki67 > 10% Ki67 ≤ 10% Total numbers
ADAPT postmenopausal
Allred <6 33 (70) 14 (30) 47 5 (71) 2 (29) 7 38 (70) 16 (30) 54
Allred 6 6 (60) 4 (40) 10 7 (28) 18 (72) 25 13 (37) 22 (63) 35
Allred 7 35 (38) 58 (62) 93 52 (24) 168 (76) 220 87 (28) 226 (72) 313
Allred 8 124 (27) 331 (73) 455 184 (17) 884 (83) 1068 308 (20) 1215 (80) 1523
ADAPT premenopausal
Allred <6 24 (75) 8 (25) 32 16 (67) 8 (33) 24 40 (71) 16 (29) 56
Allred 6 12 (75) 4 (25) 16 39 (77) 12 (23) 51 51 (76) 16 (24) 67
Allred 7 51 (73) 19 (27) 70 257 (60) 170 (40) 427 308 (62) 189 (38) 497
Allred 8 68 (68) 32 (32) 100 366 (55) 300 (45) 666 434 (57) 332 (43) 766
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METHODS
Data sets analysed
The authors identified sets of their NeoET trial data both published and
unpublished on which ER, PgR and Ki67 at diagnosis and Ki67 after
2–4 weeks’ NeoET were available. Only clinical response data were
available from the on-going ALTERNATE trial. The PALLET and IL1839/223
trials had clinical response data as well as immunohistochemical data.
The clinical trials are listed in Table 1 along with key design issues and
the number of patients that were included in the current paper from each.
The citations are given for each trial where the details of design and
inclusion/exclusion criteria are given along with the primary outcome data
for those trials that have completed and reported.
The data on POETIC were from a case-control study in which cases were
patients with recurrences within the first 5 years of follow-up with a case:
control ratio of 1:1.
We also accessed data from an audit of 454 patients treated in
Edinburgh between 2001 and 2016 with neoadjuvant letrozole for a mean
206 days.
All relevant ethical regulations were complied with and the name of the
board and institution that approved the study protocol, is included in
Table 1. The POETIC trial was approved by the London-South East Research
Ethics Committee. All patients gave informed consent within each of the
trials for the derivation of the data sourced for this study.
Immunohistochemical scoring
All of the immunohistochemical analyses were conducted centrally for the
respective trials. Ki67 scores always given as %age of cells positive. In
POETIC and PALLET ER was scored as H-score with the scores which range
from 0 to 300 being the product of the %age of cells staining at given
staining intensity as follows: 1 × %age of cells staining weakly+ 2 ×%age
of cells staining moderately+ 3 ×%age of cells staining strongly. PgR was
scored as %age of cells staining positive. In IL1839/223 both ER and PgR
were scored as H-scores. In ADAPT ER and PgR were scored as Allred
scores. In Z1031B ER was scored by Allred score; PgR was not analysed. For
trials where the H-score was calculated the %age of cells staining (at any
intensity) is also available.
Data analyses
Some of the data included have been previously published but
subgroupings and bespoke analyses were conducted specifically for this
report and have not been shown previously. Data were only included in
this report if all results for each of the biomarkers were available for a given
patient.
The data from the POETIC case-control study acted as the training set for
setting cut-offs for ER and PgR for achieving acceptable rates of Ki67 ≤
10%. ER H-score groupings of >1 and < /=75, >75 and < /150, >150 and ≤
Table 8. Summary of groups 1, 2, and 3 for PALLET/IL1839/223, and ADAPT postmenopausal and premenopausal.
PALLET/IL1839/223 ADAPT postmenopausal based on Allred
scores
ADAPT premenopausal based on Allred
scores
ER/PgR group Ki67 > 10% Ki67 ≤ 10% Total Ki67 > 10% Ki67 ≤ 10% Total Ki67 > 10% Ki67 ≤ 10% Total
n (%) n (%) n n (%) n (%) n n (%) n (%) n
1 4 (44) 5 (56) 9 44 (69) 20 (31) 64 52 (72) 20 (28) 72
2 (a) 17 (32) 36 (68) 53 159 (29) 389 (71) 548 119 (70) 51 (30) 170
2 (b) 10 (31) 22 (69) 32 59 (24) 186 (76) 245 296 (62) 182 (38) 478
2 (a+ b) 27 (32) 58 (68) 85 218 (28) 575 (72) 793 415 (64) 233 (36) 648
3 24 (15) 139 (85) 163 184 (17) 884 (83) 1068 366 (55) 300 (45) 666
Total 257 1925 1386
Remove from NeoET 36 (14%) 282 (15%) –
Remain on NeoET 221 (86%) 1643 (85%) –
ER/PgR groupings based on Allred scores. Values for Ki67 are on treatment.
Table 9. Relationship in Group 2 (or for Z1031B with ER Allred scores 6–8) between baseline cut-offs for Ki67 and the proportion of patients with
Ki67 ≤ 10% or >10%.
POETIC (Group 2 by Allred scores) Z1031B ADAPT postmenopausal (Group 2 by percentage
+ve cells)
Pre-NET Ki67 Group 2 split week-2 Ki67 Group 2 split week-3 Ki67 Group 2 split week-4 Ki67
Cut-off n (% of group 2) n (% of group split) n (% of group 2) n (% of group split) n (% of group 2) n (% of group split)
≤10% >10% ≤10% >10% ≤0% >10%
≤10% 25 (23%) 25 (100%) 0 (0%) 68 (33%) 60 (88%) 8 (12%) 251 (27.3%) 230 (91.6%) 21 (8.4%)
>10% 85 (77%) 54 (64%) 31 (36%) 139 (67%) 101 (73%) 38 (27%) 668 (72.3%) 434 (65.0%) 234 (35.0%)
≤15% 43 (39%) 39 (91%) 4 (9%) 113 (55%) 100 (88%) 13 (12%) 439 (47.8%) 381 (86.8%) 58 (13.2%)
>15% 67 (61%) 40 (60%) 27 (40%) 94 (45%) 61 (65%) 33 (35%) 480 (52.2%) 283 (59.0%) 197 (41.0%)
≤20% 58 (53%) 50 (86%) 8 (14%) 136 (66%) 121 (89%) 15 (11%) 594 (64.6%) 491 (82.7%) 103 (17.3%)
>20% 52 (47%) 29 (56%) 23 (44%) 71 (34%) 40 (56%) 31 (44%) 325 (35.4%) 173 (53.2%) 152 (46.8%)
No-cut-off 110 (100%) 79 (72%) 31 (28%) 207 (100%) 161 (73%) 46 (27%) 919 (100%) 664 (72.3%) 255 (27.7%)
The bottom line of each panel shows the proportion of patients that would have on-treatment Ki67 in these categories in the absence of using a baseline Ki67
cut-off.
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175, >175 and ≤200, >200, and ≤225, >225 and ≤250, >250 and ≤275, and
>275 were created. Approximate Allred equivalents were calculated as
Allred 2–5 (H-score >1 and ≤75), Allred 6 (H-score >75 and ≤150), Allred 7
and 8 (H-score >175). Examination of the rates of Ki67 > 10% led to the
definition of Groups 1, 2, and 3. These Allred groupings were then tested in
the ADAPT, Z1031B and PALLET and IL1839/223 data combined to increase
the numbers available.
The analysis of the relationship of 2 week Ki67 values and clinical
response was conducted in the PALLET and IL1839/223 trials having
prespecified residual tumor size cut-offs of >90%, <90% and ≥70%, <70%
and ≥50%, and >50% according to one-dimensional ultrasound
measurements.
All data are descriptive. The baseline Ki67 levels of the POETIC and
ADAPT trials were provided as medians.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The data generated and analysed during this study are described in the following
metadata record: https://doi.org/10.6084/m9.figshare.12287699 21.
The majority of the datasets supporting the findings of this study are derived from
clinical trials that have not yet been published. Other datasets are yet to be published
in association with trial secondary endpoints. For these reasons, the data supporting
the findings of this study are not publicly available, but will be made available on
reasonable request from the corresponding author, Professor Mitch Dowsett, email:
mitchell.dowsett@icr.ac.uk. Datasets that relate to the Z1031 clinical trial will be made
available to researchers on reasonable request, by contacting the ALLIANCE
Operations office (email: concepts@allianceNCTN.org) and completing an Alliance
Data Sharing Request Form.
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